secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107447
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports Q3 net loss $3.4M, cash $14.3M; DA-1726 48mg cohort data due by year-end
--------------------------------------------------------------------------------

- Net loss of $3.4M ($0.14 per share) vs $5.7M ($0.55) in Q3 2024; cash $14.3M expected to fund into 2026.
- R&D expenses fell to $1.9M from $4.5M YoY; total operating expenses $3.5M.
- Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data expected by year-end 2025.
- Phase 1 DA-1726 data: 6.3% mean weight loss, 3.9-inch waist reduction, PK supports once-weekly dosing.
- Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation, fibrosis; end-of-Phase 2 FDA meeting H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/0001104659-25-107447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465925107447/mtva-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer